# Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age

> **NCT00970307** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 421 (actual)

## Conditions studied

- Tetanus
- Diphtheria
- Haemophilus Influenzae Type b
- Poliomyelitis
- Acellular Pertussis
- Hepatitis B
- Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni

## Interventions

- **BIOLOGICAL:** GSK2202083A vaccine
- **BIOLOGICAL:** 10-valent pneumococcal vaccine (GSK 1024850A)
- **BIOLOGICAL:** Infanrix hexa™
- **BIOLOGICAL:** Menjugate®

## Key facts

- **NCT ID:** NCT00970307
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-13
- **Primary completion:** 2010-01-27
- **Final completion:** 2010-01-27
- **Target enrollment:** 421 (ACTUAL)
- **Last updated:** 2020-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00970307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00970307, "Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00970307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*